Skip to main content
Premium Trial:

Request an Annual Quote

Immucor Acquires Sirona Genomics

NEW YORK (GenomeWeb) -- Transfusion and transplantation diagnostics company Immucor announced today that it has acquired Sirona Genomics, a spinout of the Stanford Genome Technology Center.

Terms of the deal were not disclosed.

The two companies have been collaborating for several years on the development and commercialization of the Mia Fora NGS system for high-resolution HLA typing. In October 2014, Sirona announced that Immucor had given it funding to develop the technology commercially, and that Immucor would have the right of first refusal to acquire Sirona.

Mia Fora NGS was launched in December 2015 and is available for research use only in the US. In February 2016, the firms announced that they received the CE mark for the platform, which had been developed for accurate coverage and analysis of 11 HLA genes and adapted for use on the Illumina MiSeq. They also said they expect to launch a higher-volume testing kit for bone marrow registry HLA typing later this year.

"We are excited to welcome the Sirona team to our Immucor family," said Immucor Chairman and CEO Jeff Binder in a statement. "Since October 2014, the Sirona and Immucor teams have collaborated to bring to market a superior HLA typing product that provides a better matched donor for each transplant patient with less rework for the lab. With the Sirona team onboard, we will drive market adoption of Mia Fora NGS together."